Products
Alcestobart Biosimilar Monoclonal Antibody (LAG-3) for Research
Cat No.: GMP-Bios-INN-1069
Anti-LAG3/CD223 therapeutic antibody (Pre-made Alcestobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Alcestobart (development code LBL-007) is a monoclonal antibody targeting LAG3. It is developed by BeiGene and Leads Biolabs for non-small cell lung cancer, oesophageal cancer, squamous cell cancer among others. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1069-1mg | 1mg | 3090 |
| GMP-Bios-INN-1069-10mg | 10mg | |
| GMP-Bios-INN-1069-100mg | 100mg | |
| GMP-Bios-INN-1069-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Alcestobart biosimilar, Whole mAb: Anti-LAG3/CD223 therapeutic antibody |
| INN Name | Alcestobart |
| Target | LAG3/CD223 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | BeiGene;Leads Biolabs |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Oesophageal cancer;Squamous cell cancer;Colorectal cancer;Solid tumours |
| Conditions Discontinued | Lymphoma;Malignant melanoma |
| Production | na |
| Development Tech | na |
